双歧杆菌三联活菌胶囊联合黄连素片对高脂血症患者血脂、肠道菌群的影响

Effects of Bifidobacterium triple viable capsules combined with Berberine tablets on blood lipid and intestinal flora in patients with hyperlipidemia

目的探讨双歧杆菌三联活菌胶囊联合黄连素片对高脂血症患者血脂、肠道菌群的影响。方法回顾性选择2019年1月至2020年12月解放军总医院第二医学中心收治的420例高脂血症患者,按照随机数字表法分为观察组和对照组,各210例。两组均常规给予降血脂药物治疗,同时给予双歧杆菌三联活菌胶囊口服,观察组在对照组基础上联合黄连素片口服。比较两组治疗前后血清炎性因子、血脂和载脂蛋白水平及肠道菌群数量的差异;比较两组治疗期间不良反应发生情况。结果观察组治疗后白细胞介素6(IL-6)、肿瘤坏死因子-α(TNF-α)、高敏C反应蛋白(hs-CRP)水平低于对照组[(26.78±5.63)ng/L比(30.06±5.79)ng/L、(12.88±4.76)ng/L比(15.45±5.32)ng/L、(8.22±2.80)mg/L比(10.26±3.71)mg/L],差异有统计学意义(P<0.05);观察组治疗后血脂水平较对照组显著改善,并且观察组治疗后载脂蛋白AⅠ水平高于对照组[(2.00±0.45)g/L比(1.72±0.39)g/L],载脂蛋白B、载脂蛋白E水平低于对照组[(1.08±0.18)g/L比(1.20±0.22)g/L、(4.80±0.68)g/L比(5.12±0.62)g/L],差异均有统计学意义(P<0.05)。观察组治疗后粪便双歧杆菌、乳酸杆菌数量高于对照组[(8.80±0.80)lg cfu/g比(8.30±0.75)lg cfu/g、(8.85±0.64)lg cfu/g比(8.45±0.68)lg cfu/g],大肠杆菌、粪肠球菌数量低于对照组[(8.20±0.55)lg cfu/g比(8.52±0.50)lg cfu/g、(6.42±0.60)lg cfu/g比(6.84±0.65)lg cfu/g],差异均有统计学意义(P<0.05)。两组治疗后不良反应发生率比较差异无统计学意义(P>0.05)。结论高脂血症患者应用双歧杆菌三联活菌胶囊联合黄连素片,可有效降低血脂水平,调节肠道菌群,且安全性较好。

Objective To explore the effects of Bifidobacterium triple viable capsules combined with Berberine tablets on blood lipid and intestinal flora in patients with hyperlipidemia.Methods A total of 420 hyperlipidemia patients admitted to the Second Medical Center of PLA General Hospital&National Clinical Research Center for Geriatric Diseases from January 2019 to December 2020 were selected and divided into the observation group and the control group according to the random number table method,with 210 cases in each group.Both groups were routinely given lipid-lowering drugs,the control group was also given Bifidobacterium triple viable capsules orally,and the observation group was combined with Berberine tablets orally on the basis of the control group.The levels of serum inflammatory factor,blood lipid,apolipoprotein and the number of intestinal flora before and after treatment were compared between the two groups.The incidence of adverse reactions was compared between the two groups during the treatment.Results After treatment,the levels of interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),high-sensitivity C-reactive protein(hs-CRP)in the observation group were significantly lower than those in the control group:(26.78±5.63)ng/L vs.(30.06±5.79)ng/L,(12.88±4.76)ng/L vs.(15.45±5.32)ng/L,(8.22±2.80)mg/L vs.(10.26±3.71)mg/L,there were statistical differences(P<0.05).After treatment,the levels of blood lipid in the observation group were improve better than those in the control group,the levels of apolipoprotein AⅠin the observation group was higher than that in the control group:(2.00±0.45)g/L vs.(1.72±0.39)g/L;and the levels of apolipoprotein B and apolipoprotein E in the observation group were lower than those in the control group:(1.08±0.18)g/L vs.(1.20±0.22)g/L,(4.80±0.68)g/L vs.(5.12±0.62)g/L,there were statistical differences(P<0.05).After treatment,the numbers of Bifidobacterium and Lactic acid bacteria in the observation group were higher than those in the control group:(8.80±0.80)lg CFU/g vs.(8.30±0.75)lg cfu/g,(8.85±0.64)lg cfu/g vs.(8.45±0.68)lg cfu/g;and the numbers of Colon bacillus and Enterococcus faecalis in the observation group were lower than those in the control group:(8.20±0.55)lg cfu/g vs.(8.52±0.50)lg cfu/g,(6.42±0.60)lg cfu/g vs.(6.84±0.65)lg cfu/g,there were statistical differences(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions Bifidobacterium triple viable capsules combined with Berberine tablets in treatment of patients with hyperlipidemia can effectively reduce the level of blood lipid and regulate intestinal flora,with good safety.